Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of Qelbree increased 72% to $241.3 million, compared to full yea ...

Supernus Pharmaceuticals Inc (SUPN) reports robust revenue growth and strategic advancements, despite facing market ...

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s ...

Fourth quarter 2024 net sales of Qelbree® increased 60% to $74.4 million, compared to the same period in 2023. Full year 2024 net sales of ...

On a per-share basis, the Rockville, Maryland-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and stock option expense, were 75 cents per share.

The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, ...

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is $0.52 (+2500.0% Y/Y) and the consensus ...

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) will likely be releasing its earnings data after the market closes ...

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities research analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...